216 related articles for article (PubMed ID: 15900655)
1. The need for new therapeutic agents: what is the pipeline?
Shah PM
Clin Microbiol Infect; 2005 May; 11 Suppl 3():36-42. PubMed ID: 15900655
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
3. New antimicrobial agents as therapy for resistant gram-positive cocci.
Lentino JR; Narita M; Yu VL
Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228
[TBL] [Abstract][Full Text] [Related]
4. Approaches to vancomycin-resistant enterococci.
Torres-Viera C; Dembry LM
Curr Opin Infect Dis; 2004 Dec; 17(6):541-7. PubMed ID: 15640708
[TBL] [Abstract][Full Text] [Related]
5. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
6. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
7. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance.
Segreti J
Clin Microbiol Infect; 2005 May; 11 Suppl 3():29-35. PubMed ID: 15811022
[TBL] [Abstract][Full Text] [Related]
9. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
Manfredi R
Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
[TBL] [Abstract][Full Text] [Related]
12. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
13. [New antimicrobials against Gram-positive organisms].
Montejo M
Nefrologia; 2008; 28 Suppl 6():119-24. PubMed ID: 18957022
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.
Ziglam H
Expert Opin Pharmacother; 2007 Oct; 8(14):2279-92. PubMed ID: 17927483
[TBL] [Abstract][Full Text] [Related]
16. Novel pharmaceutical molecules against emerging resistant gram-positive cocci.
Manfredi R; Sabbatani S
Braz J Infect Dis; 2010; 14(1):96-108. PubMed ID: 20428664
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
19. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Steenbergen JN; Alder J; Thorne GM; Tally FP
J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]